NM_000512.5:c.318C>T

Variant summary

Our verdict is Benign. The variant received -18 ACMG points: 0P and 18B. BP4BP6_Very_StrongBP7BS1BS2

The NM_000512.5(GALNS):​c.318C>T​(p.Asn106Asn) variant causes a splice region, synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0233 in 1,612,518 control chromosomes in the GnomAD database, including 477 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.019 ( 50 hom., cov: 33)
Exomes 𝑓: 0.024 ( 427 hom. )

Consequence

GALNS
NM_000512.5 splice_region, synonymous

Scores

2
Splicing: ADA: 0.002116
2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:9

Conservation

PhyloP100: -0.902

Publications

6 publications found
Variant links:
Genes affected
GALNS (HGNC:4122): (galactosamine (N-acetyl)-6-sulfatase) This gene encodes N-acetylgalactosamine-6-sulfatase which is a lysosomal exohydrolase required for the degradation of the glycosaminoglycans, keratan sulfate, and chondroitin 6-sulfate. Sequence alterations including point, missense and nonsense mutations, as well as those that affect splicing, result in a deficiency of this enzyme. Deficiencies of this enzyme lead to Morquio A syndrome, a lysosomal storage disorder. [provided by RefSeq, Jul 2008]
GALNS Gene-Disease associations (from GenCC):
  • mucopolysaccharidosis type 4A
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet, Genomics England PanelApp

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -18 ACMG points.

BP4
Computational evidence support a benign effect (REVEL=0.187).
BP6
Variant 16-88841898-G-A is Benign according to our data. Variant chr16-88841898-G-A is described in ClinVar as [Benign]. Clinvar id is 256333.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.902 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.0194 (2948/152278) while in subpopulation NFE AF = 0.0295 (2008/68014). AF 95% confidence interval is 0.0284. There are 50 homozygotes in GnomAd4. There are 1412 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 50 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GALNSNM_000512.5 linkc.318C>T p.Asn106Asn splice_region_variant, synonymous_variant Exon 3 of 14 ENST00000268695.10 NP_000503.1 P34059Q96I49

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GALNSENST00000268695.10 linkc.318C>T p.Asn106Asn splice_region_variant, synonymous_variant Exon 3 of 14 1 NM_000512.5 ENSP00000268695.5 P34059

Frequencies

GnomAD3 genomes
AF:
0.0194
AC:
2946
AN:
152160
Hom.:
50
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00628
Gnomad AMI
AF:
0.00548
Gnomad AMR
AF:
0.0256
Gnomad ASJ
AF:
0.0231
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00434
Gnomad FIN
AF:
0.0116
Gnomad MID
AF:
0.00949
Gnomad NFE
AF:
0.0295
Gnomad OTH
AF:
0.0263
GnomAD2 exomes
AF:
0.0184
AC:
4535
AN:
245878
AF XY:
0.0188
show subpopulations
Gnomad AFR exome
AF:
0.00535
Gnomad AMR exome
AF:
0.0179
Gnomad ASJ exome
AF:
0.0198
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0117
Gnomad NFE exome
AF:
0.0282
Gnomad OTH exome
AF:
0.0207
GnomAD4 exome
AF:
0.0237
AC:
34632
AN:
1460240
Hom.:
427
Cov.:
31
AF XY:
0.0235
AC XY:
17081
AN XY:
726318
show subpopulations
African (AFR)
AF:
0.00469
AC:
157
AN:
33456
American (AMR)
AF:
0.0184
AC:
820
AN:
44572
Ashkenazi Jewish (ASJ)
AF:
0.0211
AC:
552
AN:
26112
East Asian (EAS)
AF:
0.0000504
AC:
2
AN:
39652
South Asian (SAS)
AF:
0.00453
AC:
389
AN:
85926
European-Finnish (FIN)
AF:
0.0131
AC:
695
AN:
53128
Middle Eastern (MID)
AF:
0.0233
AC:
134
AN:
5760
European-Non Finnish (NFE)
AF:
0.0275
AC:
30557
AN:
1111326
Other (OTH)
AF:
0.0220
AC:
1326
AN:
60308
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.469
Heterozygous variant carriers
0
1795
3590
5386
7181
8976
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
1110
2220
3330
4440
5550
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0194
AC:
2948
AN:
152278
Hom.:
50
Cov.:
33
AF XY:
0.0190
AC XY:
1412
AN XY:
74454
show subpopulations
African (AFR)
AF:
0.00631
AC:
262
AN:
41546
American (AMR)
AF:
0.0256
AC:
391
AN:
15298
Ashkenazi Jewish (ASJ)
AF:
0.0231
AC:
80
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5188
South Asian (SAS)
AF:
0.00435
AC:
21
AN:
4830
European-Finnish (FIN)
AF:
0.0116
AC:
123
AN:
10616
Middle Eastern (MID)
AF:
0.0102
AC:
3
AN:
294
European-Non Finnish (NFE)
AF:
0.0295
AC:
2008
AN:
68014
Other (OTH)
AF:
0.0261
AC:
55
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
154
307
461
614
768
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
38
76
114
152
190
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0257
Hom.:
222
Bravo
AF:
0.0190
Asia WGS
AF:
0.00433
AC:
15
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 15, 2019
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: GALNS c.318C>T (p.Asn106Asn) alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.018 in 245878 control chromosomes in the gnomAD database, including 68 homozygotes. The observed variant frequency is approximately 9 fold of the estimated maximal expected allele frequency for a pathogenic variant in GALNS causing Mucopolysaccharidosis Type IVA (Morquio Syndrome A) phenotype (0.002), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.318C>T in individuals affected with Mucopolysaccharidosis Type IVA (Morquio Syndrome A) and no experimental evidence demonstrating its impact on protein function have been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (2x Benign, 1x VUS). Based on the evidence outlined above, the variant was classified as benign. -

Nov 06, 2017
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mucopolysaccharidosis, MPS-IV-A Benign:3
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Nov 07, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Jun 03, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 9298823, 22521955) -

Jun 21, 2017
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.43
CADD
Benign
1.1
DANN
Benign
0.90
PhyloP100
-0.90
Mutation Taster
=67/33
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.0021
dbscSNV1_RF
Benign
0.25
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs34278797; hg19: chr16-88908306; COSMIC: COSV51938701; COSMIC: COSV51938701; API